• Cross-sectional study to compare glucose and lipid metabolism in SMI subjects treated with either Fanapt® (iloperidone), Zyprexa® (olanzapine), or Risperdal® (risperidone)
Researchers from the Massachusetts General Hospital, Psychiatry Department seek men
and women ages 18-65 that have a diagnosis of schizophrenia, schizoaffective disorder,
major depressive disorder, bipolar disorder, psychosis NOS, delusional disorder or
paranoid disorder and are treated with either Fanapt® (iloperidone), Zyprexa® (olanzapine), or
Risperdal® (risperidone). This two-month research study examines how these three
antipsychotic medications affect glucose metabolism, or how the body breaks down sugar,
in patients with serious mental illness. This study requires 3 research visits, which include
an EKG, cognitive testing, a whole body x-ray, a nutritional assessment and a fasting
blood draw. Participants are compensated up to $110. We may provide reimbursement for
your travels or provide a cab voucher. If interested, please call Shayna at (617) 912-7882 or
email SSchor@partners.org.
Institution  –  MGH - Massachusetts General Hospital, Boston, MA; Freedom Trail Clinic, Boston, MA
Principal Investigator  – David C Henderson, MD
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Schor H Shayna, CRC
Email  – sschor@partners.org
Phone  – 617 912 7882